Analysis of p21WAF1/CIP1 in primary bladder tumors - PubMed (original) (raw)
Affiliations
- PMID: 9114433
Analysis of p21WAF1/CIP1 in primary bladder tumors
L Lacombe et al. Oncol Res. 1996.
Abstract
The p21WAF1/CIP1 gene is regulated by p53 and encodes a cyclin-dependent kinase (Cdk)-inhibitor involved in senescence and cell quiescence. The role of p21 as a negative regulator of cell proliferation suggests that it may function as a tumor suppressor gene. However, only a few mutations of the p21WAF1/CIP1 gene have been reported to date. In order to assess potential p21WAF1/CIP1 gene alterations in human bladder cancer, we have examined this gene and its encoded product in a well-characterized cohort of 27 primary bladder tumors. Mobility shifts by single-strand conformation polymorphism in the p21WAF1/CIP1 gene were identified in 2 cases. Sequencing analyses revealed that one of these cases had point mutations in the 3' untranslated region, while the other case had a frame shift mutation at positions 322 (C to A) and a deletion of 8 nucleotides (323-->331; CCG-->ACG, codon 81 Arg-->Thr) that produced a stop signal at codon 83 (Gly--Stop). This tumor had a p21-negative phenotype by immunohistochemistry, but did not lose any allele. We further characterized these cases by the study of TP53 mutations using single-strand conformation polymorphism (PCR-SSCP) and sequencing, as well as immunohistochemical assays. Seven mobility shifts were identified and seven cases showed p53 nuclear accumulation. The two cases displaying mutated p21WAF1/CIP1 had wild-type TP53. It is concluded that p21WAF1/CIP1 gene aberrations are infrequent in bladder carcinoma but may be occasionally identified in primary bladder tumors.
Similar articles
- Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas.
Malkowicz SB, Tomaszewski JE, Linnenbach AJ, Cangiano TA, Maruta Y, McGarvey TW. Malkowicz SB, et al. Oncogene. 1996 Nov 7;13(9):1831-7. Oncogene. 1996. PMID: 8934528 - Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
Lee CC, Yamamoto S, Wanibuchi H, Wada S, Sugimura K, Kishimoto T, Fukushima S. Lee CC, et al. Cancer Res. 1997 Nov 1;57(21):4765-76. Cancer Res. 1997. PMID: 9354438 - Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
Migaldi M, Sgambato A, Garagnani L, Ardito R, Ferrari P, De Gaetani C, Cittadini A, Trentini GP. Migaldi M, et al. Clin Cancer Res. 2000 Aug;6(8):3131-8. Clin Cancer Res. 2000. PMID: 10955794 - [Messenger RNA expression of p21WAF1/CIP1 in colorectal carcinoma tissues].
Kobayashi S, Matsushita K, Isono K. Kobayashi S, et al. Nihon Geka Gakkai Zasshi. 1998 Jul;99(7):457-62. Nihon Geka Gakkai Zasshi. 1998. PMID: 9742528 Review. Japanese. - p21WAF1 mutations and human malignancies.
Shiohara M, Koike K, Komiyama A, Koeffler HP. Shiohara M, et al. Leuk Lymphoma. 1997 Jun;26(1-2):35-41. doi: 10.3109/10428199709109155. Leuk Lymphoma. 1997. PMID: 9250785 Review.
Cited by
- Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer.
Koga F, Kitahara S, Arai K, Honda M, Sumi S, Yoshida K. Koga F, et al. Jpn J Cancer Res. 2000 Apr;91(4):416-23. doi: 10.1111/j.1349-7006.2000.tb00961.x. Jpn J Cancer Res. 2000. PMID: 10804290 Free PMC article. - Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.
Cazier JB, Rao SR, McLean CM, Walker AK, Wright BJ, Jaeger EE, Kartsonaki C, Marsden L, Yau C, Camps C, Kaisaki P; Oxford-Illumina WGS500 Consortium; Taylor J, Catto JW, Tomlinson IP, Kiltie AE, Hamdy FC. Cazier JB, et al. Nat Commun. 2014 Apr 29;5:3756. doi: 10.1038/ncomms4756. Nat Commun. 2014. PMID: 24777035 Free PMC article. - Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.
Mainprize TG, Taylor MD, Rutka JT, Dirks PB. Mainprize TG, et al. J Neurooncol. 2001 Feb;51(3):205-18. doi: 10.1023/a:1010671908204. J Neurooncol. 2001. PMID: 11407593 Review. - Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.
Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Horner JW 2nd, DePinho RA. Chin L, et al. Genes Dev. 1997 Nov 1;11(21):2822-34. doi: 10.1101/gad.11.21.2822. Genes Dev. 1997. PMID: 9353252 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous